SELLAS Life Sciences Group, Inc. — Director's Dealing 2010

Jan 19, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-01-14

Reporting Person: Tata Amy B (Principle Acctg Officer & Cont)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-01-14	Stock Option	$5.66	A	12081	Acquired	2020-01-14	Common Stock (12081)	Direct

Footnotes

F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.

F2: Per share.

F3: 755 of the options vested on April 14, 2010 with the remaining shares vesting in equal installments on each of the next 14 quarterly anniversaries of April 14, 2010 and 756 of the option vesting on January 14, 2014. All options will be fully vested on January 14, 2014.